Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
Fiche publication
Date publication
juin 2016
Journal
Lancet (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr FORNECKER Luc-Matthieu, Dr OJEDA-URIBE Mario
Tous les auteurs :
Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G
Lien Pubmed
Résumé
Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm studies suggest that addition of rituximab to these regimens could improve patient outcomes. Our objective was to test this possibility in a randomised trial.
Mots clés
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Biomarkers, Tumor, analysis, Bone Marrow Neoplasms, drug therapy, Burkitt Lymphoma, chemistry, Central Nervous System Neoplasms, drug therapy, Cyclophosphamide, administration & dosage, Cytarabine, administration & dosage, Doxorubicin, administration & dosage, Drug Administration Schedule, Female, France, Humans, Hydrocortisone, administration & dosage, Injections, Intravenous, Male, Methotrexate, administration & dosage, Methylprednisolone, administration & dosage, Middle Aged, Neoplasm Staging, Odds Ratio, Patient Selection, Prednisone, administration & dosage, Proportional Hazards Models, Rituximab, administration & dosage, Treatment Outcome, Vincristine, administration & dosage
Référence
Lancet. 2016 Jun 11;387(10036):2402-11